GLAXOSMITHKLINE PHARMACEUTICALS LTD. Q4 FY25 Results
GLAXOQ4 FY25 ResultsAnnounced 13 May 2025, 04:04 pm| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 974.37 | 2.6% |
| Total Income | 1.0K | 3.1% |
| Expenditure | 656.48 | 2.9% |
| PBT | 358.57 | 16.4% |
| Net Profit | 262.87 | 14.3% |
| OPM | 34.20% | 7.43pp |
| NPM | 25.90% | 2.55pp |
| EPS | 15.52 | 14.4% |
GSK Pharmaceuticals Reports 9% Revenue Growth and 32% Increase in Profit for FY2024-25
13 May 2025 · 13 May 2025, 06:58 pm
Summary
GSK Pharmaceuticals Limited announced its financial results for the year ended March 31, 2025. The company reported full year revenue of Rs. 3723 crores, a growth of 9%. Profit After Tax before exceptional items increased by 32% to Rs. 915 crores and EBITDA margins increased by 500 basis points (bps) to 31.4%. Key brands including Augmentin, Calpol, Ceftum, T-Bact, and Trelegy have played a significant role in driving growth throughout the year. The company is on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer and Jemperli (Dostarlimab), an immunotherapy approved for the second-line treatment of endometrial cancer.
Key Highlights
- 1
9% growth in full year revenue
- 2
32% increase in Profit After Tax before exceptional items
- 3
500 bps increase in EBITDA margins
- 4
Key brands such as Augmentin, Calpol, Ceftum, T-Bact, and Trelegy driving growth
- 5
On track to launch oncology assets Zejula and Jemperli
- 6
Revenue of Rs. 966 crores for Q4 2024-25, a like-to-like growth of 6%
- 7
Profit After Tax for Q4 2024-25 stood at Rs.260 crores
Management Comments
Bhushan Akshikar
Managing Director, GlaxoSmithKline Pharmaceuticals Limited
Our diversified portfolio of General Medicines, Specialty, and Vaccines has shown improved growth due to sustained innovation, enhanced Healthcare Professionals (HCP) engagement and rapid digital acceleration. This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customers. Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult vaccination ecosystem in the country. We remain committed to delivering sustained above-market growth and strong shareholder returns. In FY2025-26, we will continue to focus on our innovative portfolio through the launch of our oncology assets.
Informational and educational content only. Not investment advice.